Bank of Jackson Hole Trust Takes Position in Zoetis Inc. (NYSE:ZTS)

Bank of Jackson Hole Trust purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,932 shares of the company’s stock, valued at approximately $641,000.

A number of other institutional investors also recently modified their holdings of ZTS. AMF Tjanstepension AB raised its position in shares of Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after purchasing an additional 20,001 shares during the period. Creative Planning increased its position in Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock worth $17,663,000 after acquiring an additional 7,170 shares during the period. Howard Capital Management Group LLC increased its position in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares during the period. Cyndeo Wealth Partners LLC bought a new position in Zoetis during the third quarter worth $244,000. Finally, Allspring Global Investments Holdings LLC increased its position in Zoetis by 8.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock worth $10,882,000 after acquiring an additional 4,107 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ZTS shares. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average price target of $214.90.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Down 0.7 %

Shares of NYSE ZTS opened at $156.43 on Wednesday. The firm’s 50-day simple moving average is $167.70 and its 200 day simple moving average is $178.44. The company has a market cap of $70.05 billion, a price-to-earnings ratio of 28.60, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts expect that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis’s dividend payout ratio is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.